The current study, NCT05785767, is a randomized, double-blind, phase 2/3 study evaluating fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) versus cemiplimab alone in the first-line treatment of advanced non-small-cell lung cancer. The gene discussed is LAG3; the disease is non-small cell lung carcinoma.